Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Asieris Pharma Partners with SPH Keyuan to Commercialize Cevira – World’s First Non‑Surgical Cervical Precancer Treatment Launches in China

Fineline Cube Mar 25, 2026
Company Deals

Sciwind Biosciences Files Hong Kong IPO Prospectus – GLP‑1 Obesity Pipeline Targets R&D Funding for Weight Management Franchise

Fineline Cube Mar 25, 2026
Company Deals

Kali Therapeutics Licenses KT501 to Sanofi – $1.23B Deal for Trispecific T-Cell Engager Targets Autoimmune Diseases

Fineline Cube Mar 24, 2026
Company Deals Drug

Belief BioMed Partners with Grand Life Sciences on BBM-H803 – AAV Gene Therapy for Hemophilia A Targets Greater China Market

Fineline Cube Mar 24, 2026
Company Deals

Hanmi Pharmaceutical Partners with Chongqing Zhongfu – Amlodipine/Losartan Fixed-Dose Combo Targets China Out-of-Hospital Digital Market

Fineline Cube Mar 24, 2026
Policy / Regulatory

China NHC Elevates Chikungunya and SFTS to Category B Status – Enhanced Surveillance and Control Measures Effective April 2026

Fineline Cube Mar 25, 2026
Company Drug

Zhifei Bio Initiates Phase I Study for DTaP-Hib Quadrivalent Vaccine – Component Combination Targets Pediatric Immunization Compliance

Fineline Cube Mar 25, 2026
Company Drug

Changchun High-Tech Wins FDA Orphan Drug Designation for GenSci128 – TP53 Y220C Reactivator Targets Gastric Cancer

Fineline Cube Mar 25, 2026
Policy / Regulatory

Shanghai Healthcare Administration Pushes for 11th Round of VBP

Fineline Cube Apr 21, 2025

Shanghai’s Healthcare Security Administration (HSA) bureau held a work conference on April 16, 2025, to...

Company Medical Device

Vivolight’s Multimodal Coronary OCT System Gains FDA Clearance

Fineline Cube Apr 21, 2025

Shenzhen-based minimally invasive laser medical device firm Vivolight Medical Device & Technology Co., Ltd has...

Company Drug

Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101

Fineline Cube Apr 21, 2025

China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced that it has received clinical...

Company Drug

Sanofi’s Dupixent Approved by FDA for Chronic Spontaneous Urticaria

Fineline Cube Apr 21, 2025

France-based pharmaceutical major Sanofi (EPA: SAN, NASDAQ: SNY) has announced that the US Food and Drug...

Company Drug

Biogen’s High-Dose Spinraza Regimen Accepted for CDE Review in China

Fineline Cube Apr 21, 2025

US-based Biogen Inc. (NASDAQ: BIIB) announced that the Center for Drug Evaluation (CDE) in China...

Company Drug

Sichuan Biokin Gains NMPA Approval for Phase II Trials of BL-B01D1 in Combination Therapies

Fineline Cube Apr 21, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical...

Company Drug

Walvax Biotech Gains NMPA Clinical Clearance for 20-Valent Pneumococcal Vaccine

Fineline Cube Apr 21, 2025

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced receiving clinical trial clearance from the...

Company

Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs

Fineline Cube Apr 21, 2025

hina-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has released its 2024 financial report. In...

Company Deals

Shandong Lukang Plans Private Placement to Raise RMB1.2 Billion for Drug Development

Fineline Cube Apr 21, 2025

China-based Shandong Lukang Pharmaceutical Co., Ltd. (SHA: 600789), a state-owned integrated pharmaceutical company, has announced...

Company Drug

Dizal’s Golidocitinib Receives CSCO Class 1 Recommendation for PTCL Treatment

Fineline Cube Apr 21, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that its drug Gaoruizhe (golidocitinib) has received...

Company Drug

Humanwell Healthcare Gains NMPA Approval for HWS116 Clinical Trials in Advanced Solid Tumors

Fineline Cube Apr 21, 2025

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that it has received clinical...

Company Medical Device

Medtronic Wins FDA Approval for Simplera Sync Sensor in MiniMed 780G System

Fineline Cube Apr 21, 2025

US-Irish medical technology firm Medtronic plc (NYSE: MDT) has secured marketing approval from the US...

Company Drug

Suzhou Zelgen Gains NMPA Approval for ZG006 in Small Cell Lung Cancer Study

Fineline Cube Apr 21, 2025

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) has received clearance from the National Medical...

Company Drug

Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Trials of HRS-1167 and SHR-4658

Fineline Cube Apr 21, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced the receipt of clinical trial...

Company Drug

AstraZeneca’s Truqap Granted NMPA Approval for Breast Cancer Treatment

Fineline Cube Apr 21, 2025

China’s National Medical Products Administration (NMPA) has approved AstraZeneca’s (AZ, NASDAQ: AZN) Truqap (capivasertib) for...

Company Drug

Novo Nordisk’s Sogroya Approved for Use in Boao Lecheng Medical Zone

Fineline Cube Apr 21, 2025

Denmark-based Novo Nordisk (NYSE: NVO) has announced that its long-acting somatotropin Sogroya (somapacitan) has been...

Company Drug

Regeneron’s Eylea HD Receives FDA Priority Review for Macular Edema Treatment

Fineline Cube Apr 18, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGNN) announced that the U.S. Food and Drug Administration (FDA) has...

Company Drug

BRL Medicine Secures IND Approval for BRL-301 CAR-T Therapy in R/R B-NHL

Fineline Cube Apr 18, 2025

Shanghai-based BRL Medicine Inc. has announced that it has received Investigational New Drug (IND) approval...

Company Deals

Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment

Fineline Cube Apr 18, 2025

French pharmaceutical giant Sanofi (EPA: SAN, NASDAQ: SNY) has entered into a licensing agreement with...

Company

Bayer Commissions Pennsylvania Facility Expansion After $44 Million Investment

Fineline Cube Apr 18, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) has completed a 70,000-square-foot expansion at its Myerstown,...

Posts pagination

1 … 149 150 151 … 640

Recent updates

  • Zhifei Bio Initiates Phase I Study for DTaP-Hib Quadrivalent Vaccine – Component Combination Targets Pediatric Immunization Compliance
  • Changchun High-Tech Wins FDA Orphan Drug Designation for GenSci128 – TP53 Y220C Reactivator Targets Gastric Cancer
  • China NHC Elevates Chikungunya and SFTS to Category B Status – Enhanced Surveillance and Control Measures Effective April 2026
  • Gan & Lee’s Bonfaglutide Wins NMPA Approval for OSA Study – Biweekly GLP‑1 Expands to Sleep Apnea Indication
  • Clover Bio Reports Positive SCB‑1019 Phase I Data – RSV PreF Vaccine Demonstrates Superior Booster Response vs. GSK’s Arexvy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Zhifei Bio Initiates Phase I Study for DTaP-Hib Quadrivalent Vaccine – Component Combination Targets Pediatric Immunization Compliance

Company Drug

Changchun High-Tech Wins FDA Orphan Drug Designation for GenSci128 – TP53 Y220C Reactivator Targets Gastric Cancer

Policy / Regulatory

China NHC Elevates Chikungunya and SFTS to Category B Status – Enhanced Surveillance and Control Measures Effective April 2026

Company Drug

Gan & Lee’s Bonfaglutide Wins NMPA Approval for OSA Study – Biweekly GLP‑1 Expands to Sleep Apnea Indication

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.